Dark Horse Consulting Group and KunTuo Announce Memorandum of Understanding Providing Cell and Gene Therapy Developers with an Accelerated Path to Clinical Development in China

AI Briefing

• – DHCG and KunTuo form partnership to streamline cell and gene therapy clinical trials in China.
• – MOU aims to provide accelerated clinical development path for cell and gene therapy developers.
• – Combined expertise to support China-based clinical trials and regulatory compliance.